Background An audit of tumour marker requests was carried out in Northern Ireland. The aims were to establish the extent of inappropriate requesting, to effect change in request practice if required, and to standardize laboratory reports for tumour markers.
Introduction
The population of Northern Ireland is 1.69 million in a land area of 5500 square miles, with approximately 45% of the population living within 15 miles of the centre of Belfast. Cancer services have developed to include four peripheral cancer units where a limited number of chemotherapy regimes (mainly for breast, colorectal and lung cancers) can be given, and a Regional Cancer Centre that is currently being built in Belfast for inpatient and outpatient radiotherapy and chemotherapy. The work of the cancer centre is currently being done across two sites.
The cancer centre and each peripheral cancer unit have on-site laboratory services. At the time of the baseline survey of the current audit, all of these laboratories analysed prostate speci¢c antigen (PSA) and four of them also analysed some or all of the other most commonly requested tumour markers. The latter were all situated in Belfast. Rationalization of tumour marker testing occurred after the baseline survey was completed. This resulted in a reduction to two laboratories in Northern Ireland that analysed tumour markers other than PSA.
Requests for tumour marker measurements are rising at an average annual rate of 15% in Northern Ireland (unpublished observation). PSA is the exception, with an annual rate of increase of 2%. The majority of requests for alphafetoprotein (AFP), human chorionic gonadotropin (hCG), CA19.9 and CA15.3 originate from hospital wards and clinics, with only 4% of requests from family practitioners (FPs). The same is not true of PSA, carcinoembryonic antigen (CEA) and CA125, with 45%, 11% and 19% respectively of these requests coming from FPs. The diagnostic role of PSA is the likely explanation for such a high percentage of requests from this source. If this is also the reason for so many requests for CEA and CA125 from FPs then it may suggest a lack of understanding about the diagnostic capabilities of these two markers. Clinical details provided on tumour marker request forms are generally limited but they sometimes suggest inappropriate requesting. The low speci¢city and sensitivity of these tests limit their use in many clinical settings, and may even be detrimental if inappropriate conclusions are drawn from results.
The Northern Ireland Regional Chemical Pathology Audit Group decided to conduct an audit of tumour marker requesting. The aims of the audit were to establish the extent of inappropriate requesting of tumour markers; to establish laboratory practice in relation to analysis and reporting of tumour markers; to e¡ect intervention if inappropriate requesting or laboratory practices were found; and to re-audit post-intervention.
Methods
A baseline audit of tumour marker requests was conducted in November 1999. Questionnaires were issued with each report for CEA, CA125, CA19.9, CA15.3, AFP and hCG (seeTable1a). This amounted to a total of 1336 questionnaires, of which 603 went to the cancer centre, 259 to the cancer units, 364 to hospital doctors and 110 to FPs. Owing to the large number of requests and the many di¡erent issues concerning PSA testing, it was decided not to include this test in the audit.
Standards for the correct use of tumour markers do not exist, so guidelines produced by the Association of Clinical Biochemists in Ireland (ACBI), 1 the European Group on Tumour Markers (EGTM), 2^4 and the American Society of Clinical Oncology (ASCO) 5 were used to assess if the requestor had both used the correct tumour marker for the speci¢c malignancy suspected and applied the measurement of tumour markers correctly (e.g., monitoring or diagnosis).
Questionnaires designed to audit laboratory practice were sent at the time of the baseline survey to the four laboratories that analysed the tumour markers included in the audit (see Table 1b ).
Following assessment of the appropriateness of requests based on questionnaire replies, it was decided that intervention was required to increase awareness of the limitations of tumour markers among clinicians that do not specialize in oncology. To this end, the following measures were undertaken:
An information booklet containing guidelines produced by the ACBI 1 was sent to all clinicians who requested tumour markers during the baseline survey.
The audit report was published in the Northern Ireland Medical Review, 6 which is distributed to all clinicians in Northern Ireland.
A post-intervention study was then carried out on all requests made between 4 and 15 February 2002, inclusive. The tumour markers audited were the same as before except for CA15.3, analysis of which is no longer carried out in Northern Ireland. A new questionnaire was designed to speci¢cally address the issues raised following the baseline audit (seeTable 1c). A total of 775 of these were sent, of which 271 were sent to the cancer centre, 155 to the cancer units, 256 to hospital doctors and 93 to FPs. These questionnaires were sent to the FP or consultant to whom the patient was registered even though the requesting physician may not have been the consultant, but another member of the medical team.
Results
The audit of laboratory practice at the time of the baseline survey showed that interpretative comments on tumour marker reports were supplied by one laboratory, and that two laboratories provided cumulative reports. There were also some di¡erences in reference ranges quoted among users of the same method (see Table 2 ). In the case of hCG, this was because one laboratory used data provided in the manufacturer's kit insert, while another used inhouse data. Di¡erences in reference ranges for CEA between Abbott AxSYM (Abbott Diagnostics Division, Maidenhead, UK) users occurred because scienti¢c literature was used by one laboratory, while the other used data from the kit insert. While one laboratory quoted a separate upper limit for smokers, the other provided a general comment that included smoking as a possible cause of elevated CEA levels. Post-intervention, the two laboratories that currently analyse tumour markers both use the Abbott AxSYM analyser, cumulative reports, and standardised reference ranges.
Replies were obtained for 47% of questionnaires sent out in the baseline survey, and 58% of questionnaires in the post-intervention survey. There were no di¡erences in response rates between the cancer centre, the cancer units, hospital doctors or FPs. The conclusions of the baseline survey were that 80% of requests for tumour markers were appropriate in relation to the source of tumour for which the marker was requested (see Fig. 1 were made to screen for the presence of a suspected malignancy, and the index of suspicion was low in 35% of these cases. There were also an inappropriately high number of requests for multiple tumour markers, with 5% requesting more than two markers.
Comparisons of results pre-and post-intervention are shown in Table 3 . The percentage of requests used to screen for the presence of a suspected tumour has remained the same after intervention, with 65% of these requestors stating that their index of suspicion was low. However, 36% of these were CA125 requests made appropriately for patients attending a familial ovarian cancer screening clinic, and a further 7% were AFP requests for patients who were at known risk of hepatoma. The majority of requests made post-intervention were still for one tumour marker only (83%), but a few clinicians requested four or ¢ve tumour markers (see Table 3c ). The request pattern for oncology for the same time period showed that 66% of requests were for one marker, 32% for AFP and hCG and 2% for CEA and CA19.9.
All questionnaires returned from oncology sources stated that the tumour markers were being used to monitor therapy and to look for early evidence of relapse. Requestors that used tumour markers either to determine the source of the primary tumour, or to screen for the presence of a suspected tumour (and therefore oncologists were excluded from this) were asked if the tumour marker helped determine the source. Questionnaire replies showed that 91% of requestors stated that they did not help determine source (see Table 4a ). Requestors were also asked if the tumour marker levels helped guide or change patient management, and 66% stated that they did not (see Table 4b ).
Comments were provided as to reasons why the tumour marker level did or did not help to determine the source of the primary tumour and guide or change patient management on 55% of questionnaire replies during the post-intervention survey. Comments appeared to be appropriate in 72% of these because the requestors were aware of the limitations of tumour markers with regard to identifying tumour source, and because further investigations were undertaken even though tumour marker levels were not elevated. Benign causes of elevated marker levels were also stated when appropriate.
Comments that appeared to be inappropriate for the information provided showed that the tumour markers requested were inappropriate either for the tumour sites or for the type of tumour suspected. The comments also showed that some requestors have unrealistic expectations in relation to the amount of reassurance that can be given to patients with low tumour marker levels, with 8% stating that normal tumour marker levels provided reassurance for the patient. A number of consultants stated that the tumour marker requests were made inappropriately by junior sta¡.
Questionnaire replies obtained during the postintervention survey for requests for four or ¢ve tumour markers are shown in Table 5 .
Although the baseline survey showed that 60% of clinicians thought that interpretative comments on tumour marker reports would be useful, only 40% of requests received during the audit provided clinical details and the majority of these simply stated the source of the unknown or suspected tumour. As expected, clinicians familiar with the use of tumour markers, such as oncologists and gynaecologists, did not require interpretative comments.
Discussion
The Audit Group recommended that laboratories should not routinely provide interpretative comments on all tumour marker reports due to the potential for misleading in the absence of clinically relevant information. It would be appropriate, however, to provide comments as outlined by the Royal College of Pathologists' guidelines. 7 This occurs most often when relevant clinical details are provided by a clinician who is likely to be unfamiliar with tumour markers. The audit group also concluded that laboratories should provide cumulative reports for tumour markers, due to the importance of trend rather than absolute levels, and as recommended by the European Group on Tumour Markers (EGTM). 8 Rationalization of the number of sites assaying tumour markers in Northern Ireland has simpli¢ed implementation of recommendations. One laboratory is situated on a peripheral cancer unit site and analyses tumour markers for this unit and for surrounding FPs. The other laboratory is situated on the cancer centre site and analyses all tumour markers daily for the rest of Northern Ireland (the cancer centre, the three remaining peripheral cancer units and the FPs for these catchment areas). The peripheral cancer units are satis¢ed with turnaround time (unpublished communications). Coincidental rationalization of tumour marker assays has ensured continuity of results when patients are transferred from FPs or hospital doctors to any of the cancer units or to the cancer centre.
Initial ¢ndings from the audit of requestors showed that most requests for tumour markers were made and interpreted appropriately, but that a large number of Ann Clin Biochem 2004; 41: 378-384 Table 5 . Post-intervention questionnaire replies for requests for four or five tumour markers. Two further requests for five tumour markers were received, but the questionnaires were not returned clinicians also used these tests to screen for malignancy. The re-audit of tumour marker requests showed that the request pattern had not been changed by actions taken following the initial audit in 1999. The majority of requestors still used tumour markers to screen for suspected malignancy, even though the index of suspicion was low in 65% of cases. Although 91% of tests used to screen for malignancy did not help determine the source of the primary tumour, this was because the site was known in most cases, e.g. familial ovarian screening, screening ovarian cysts, screening following removal of tumour. In a few cases, the site was not established prior to requesting tumour markers, and normal levels did not assist the diagnosis. A recent audit in the north of England also found that tumour markers were being requested to screen for malignancy either before results of a tissue biopsy were available, or without performing a biopsy 9 . In assessing if a tumour marker request was appropriate for the type of tumour, this audit found that 17% of CA125 and 26% of CA15.3 requests were made for men. In Northern Ireland, 18% of CA125 requests were made for non-ovarian suspected or known sites (men and women), and all requests for CA15.3 were made for suspected or known breast cancer. Comparison of the two audits is di⁄cult because of the di¡erent standards used to assess if a tumour marker request was appropriate, but request patterns appear to be similar for CA125.
The re-audit showed that most requests were again appropriate for the source of tumour, and that requests for four or ¢ve tumour markers were limited mostly to one source over the two-week period of the re-audit. Most of the requests for three tumour markers were for CEA, CA125 and CA19.9, and they were being used to investigate suspected gastrointestinal (GI) tumours. Requests for multiple markers do not greatly improve the speci¢city or sensitivity of the individual markers when looking for GI tumours. 10 Even when the correct individual marker is used appropriately for the suspected GI site of malignancy, lack of sensitivity and speci¢city limits the diagnostic ability of these markers. 3 Guidelines produced by various organizations often recommend which markers should be measured in speci¢c malignancies, but there can be di¡erences in the recommendations produced by each. 11 When compared to recommendations relating to ovarian cancer from ¢ve other groups, for example, only the Standards, Options and Recommendations (SOR) project in France recommend the additional measurement of CEA and CA19.9 for ovarian cancer patients in the absence of raised CA125 levels at presentation. 11 They also suggest that AFP and hCG should be measured in younger women to exclude germ cell tumours. Even given this liberal approach to tumour marker requesting, requests for all ¢ve markers for ovarian cancer should almost never occur, as shown in Table 5 . All other current guidelines agree that for the tumour markers included in this audit only AFP and hCG should be used for diagnosis or case-¢nding. 8 CA125 can be useful to screen women with a strong family history of ovarian cancer and in the di¡erential diagnosis of a pelvic mass. 12 Tumour marker request patterns from oncology cannot be compared to request patterns from other non-specialists. Oncologists have de¢ned protocols for the use of tumour markers, and all of their requests are made to either get early evidence of relapse, or to change therapy in progressive disease. Similarly, the majority of requests from gynaecologists are for CA125 and these are used in conjunction with ovarian ultrasound to screen patients who are perceived to be at increased risk of developing ovarian cancer by virtue of personal or family history.
Undoubtedly, FPs and medical and surgical clinicians are often faced with the diagnostic dilemmas. In circumstances where there is a medium to high index of suspicion for malignancy, the measurement of the appropriate tumour marker should not be discouraged. Pre-treatment marker levels are very useful when assessing response to treatment. Some FPs, however, appear to use CEA inappropriately on patients presenting with altered bowel habit. The amount of information that could be returned on the questionnaire was limited, so it is di⁄cult to judge if other factors had been taken into account when such requests were made. When the index of suspicion for colorectal cancer is low, it is inappropriate to request CEA and to o¡er the patient reassurance when the levels are low. It may therefore be a useful exercise to distribute information relating the percentage positive CEA levels found in patients with bowel cancer to these FPs.Wanebo et al. 13 found that the proportion of patients with CEA levels greater than 5 mg/L were 3%, 25%, 45%, and 65% for Dukes' grade A, B, C, and D disease, respectively.
Education is undoubtedly required for requestors whose comments showed that they were unaware of the diagnostic limitations of tumour markers, or who requested tumour markers that were inappropriate for the source of tumour. Those requestors whose comments demonstrated that they were aware of the limitations but still requested the markers under inappropriate circumstances have to be persuaded that there is little bene¢t to be gained from these requests. Intervention studies that attempt to modify the appropriateness of clinicians' test ordering have shown that this can be di⁄cult to achieve. 14 Interventions that have shown both success and failure have included clinician education, laboratory requisition form changes, guideline development and implementation, audit, and presentation of laboratory charges. Audit and feedback have been shown to be successful strategies used to reinforce desired practices. 15 Similarly, implementation of guidelines and use of targeted reminders can change practice. The results of this audit have shown that intervention by clinician education, distribution of guidelines, audit and feedback have not been successful strategies for changing tumour marker request patterns of nonspecialists. Perhaps we need to use the additional ¢nancial incentive and present our clinicians with laboratory charges on all reports before we can e¡ect change in requesting patterns for these tests.
Conclusion
Most requests for tumour markers were appropriate according to the information returned. There were still a number of requests however, that appeared to suggest misuse of tumour markers. Despite circulation of an information booklet containing the ACBI guidelines, and an audit report, some clinicians still choose to use tumour markers such as CEA, CA125 and CA19.9 as diagnostic aids. Other intervention strategies will be required to speci¢cally target these clinicians.
